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A B S T R A C T
Background: As part of the UK National Institute for Health and Care
Excellence (NICE) single technology appraisal process, independent evi-
dence review groups (ERGs) critically appraise a company’s submission
relating to a speciﬁc technology and indication.Objectives: To explore the
type of additional exploratory analyses conducted by ERGs and their
impact on the recommendations made by NICE.Methods: The 100 most
recently completed single technology appraisals with published guidance
were selected for inclusion. A content analysis of relevant documents was
undertaken to identify and extract relevant data, and narrative synthesis
was used to rationalize and present these data. Results: The types of
exploratory analysis conducted in relation to companies’ models were
ﬁxing errors, addressing violations, addressing matters of judgment, and
the provision of a new, ERG-preferred base case. Ninety-three of the 100
ERG reports contained at least one of these analyses. The most frequently
reported type of analysis in these 93 ERG reports related to the category
“Matters of judgment,” which was reported in 83 reports (89%). At least
one of the exploratory analyses conducted and reported by an ERG is
mentioned in 97% of NICE appraisal consultation documents and 94% of
NICE ﬁnal appraisal determinations, and had a clear inﬂuence on
recommendations in 72% of appraisal consultation documents and 47%
of ﬁnal appraisal determinations. Conclusions: These results suggest that
the additional analyses undertaken by ERGs in the appraisal of company
submissions are highly inﬂuential in the policymaking and decision-
making process.
Keywords: evidence review groups (ERGs), health policy, National
Institute for Health and Care Excellence (NICE), single technology
appraisal (STA).
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.
Introduction
The National Institute for Health and Care Excellence (NICE) single
technology appraisal (STA) process is undertaken for a technology
for a single indication [1]. This process involves the submission of
an evidence dossier by the manufacturer of the technology. One of
nine independent evidence review groups (ERGs) then undertakes
a critical appraisal of this submission and produces a report. As
part of this process, the ERG might undertake additional analyses,
so-called exploratory analyses, to explore uncertainties around the
company’s model and their implications for decision making. The
number and type of these exploratory analyses vary between
appraisals. The ERG reports are a central component of the
evidence considered by the NICE Technology Appraisal Commit-
tees (ACs) in their deliberations. The ﬁndings of the AC are used to
produce an appraisal consultation document (ACD) and, after
further considerations and a consultation period, a ﬁnal appraisal
determination (FAD), which result in NICE guidance.
The aim of this research was to develop an understanding of the
number and type of exploratory analyses undertaken by the ERGs
within the NICE STA process and to understand how these analyses
have been used by NICE ACs in their decision-making process. For
the purpose of this research, an exploratory analysis was deﬁned as
any additional analysis generating an incremental cost-effectiveness
ratio (ICER) and was included in the ERG report section as “Explor-
atory and sensitivity analyses undertaken by the ERG.” This is most
commonly reported as section 6 of an ERG report, on the basis of the
suggested ERG report template. This study aimed to address the
following objectives:
1. to identify exploratory analyses conducted by the ERG, as
deﬁned earlier;
2. to identify ERG approaches to the exploratory analyses of
economic evidence submitted by companies for NICE STAs
and to categorize these approaches by type of analysis
performed; and
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3. to make an assessment of the degree to which the exploratory
analyses inﬂuenced committees’ considerations and
recommendations.
This article should be read in conjunction with the mono-
graph by Kaltenthaler et al. [2], which reports on the frequency of
exploratory analyses in ERG reports and the extent to which they
might be predicted by factors such as company, ERG group, and
disease area. The recently published work of Ghabri et al. [3] has
considered some similar issues with reference to the cost-
effectiveness analyses in manufacturer submissions to the
French National Authority for Health. The ﬁndings of the present
study will also be considered in this context.
Methods
The 100 most recently completed STAs (since 2009) for which
ﬁnal guidance has been published were selected for inclusion in
the analysis. A list of the STAs included in this analysis is
provided in the appendix to the article by Kaltenthaler et al. [2].
The research required extraction of relevant data from more than
400 separate documents, which were made available to the
project team by NICE. These included unredacted versions of
the ERG reports (used by the ACs), the ﬁrst ACD issued (sub-
sequent ACDs were not considered), and the ﬁrst FAD (when
more than one FAD had been produced). A data extraction tool
was formulated to extract relevant data to address the project
objectives. STA reports, ACDs, and FADs all have a basic, stand-
ard structure, which facilitated data extraction. The ERG reports
have a speciﬁc “Exploratory” or “Additional analyses” section,
usually section 6, from which the data on exploratory analyses
were extracted. Nevertheless, ERG reports can vary greatly in
their level of detail and their description of analyses. A ﬁnal
agreed data extraction tool was developed after a piloting
process. The categories of exploratory analyses to be used in this
study were based on discussions with the whole project team and
an existing relevant published taxonomy of errors and other
threats to the credibility of health economic models [4]. This
approach is similar to that of framework analysis techniques for
developing an a priori framework for coding qualitative data [5].
The categories were deﬁned to facilitate consistency of coding
and were amended following the piloting process. The category
“Matters of judgment” was originally composed of three more
speciﬁc categories: 1) uncertainty and evidence variation, 2)
alternative data, and 3) ERG subjective judgment. It was, how-
ever, found that the descriptions of the analyses in the reports
were often too vague to ensure that the information was being
interpreted and coded consistently into one of these speciﬁc
categories. For this reason, a single, broader category of “Matters
of judgment” was created. The ﬁnal four agreed categories of
exploratory analyses are listed inT1 Table 1. This simple scheme
facilitated consistency of coding between data extractors.
The sevenQ4 parts of the data extraction tool are outlined in
QT2 Table 2. All data extractions were double-checked by at least two
researchers. Some of the data extraction was simple and straight-
forward, but researchers sometimes had to exercise interpreta-
tion for data relating to exploratory analyses, for example,
whether speciﬁc analyses inﬂuenced AC recommendations. To
address issues of interpretation such as this, the key data used in
the synthesis were then reduced to whether just “one or more”
exploratory analyses were explicitly cited as having an inﬂuence
on a recommendation. Such decisions were taken to make the
most of the data.
A narrative synthesis was performed on the extracted data
from the 100 ERG reports [6]. This involved summarizing the key
data through text and tables and then using narrative to highlight
any potentially important patterns or relationships in the data.
This approach was taken because the large number of reports
and documents prevented meaningful, in-depth analysis of the
text using qualitative methods, but the number of reports was
not large enough to permit meaningful statistical analysis of the
data. In conducting the synthesis, the following assumptions
were made:
1. Every exploratory analysis had to have a separately reported
ICER. If an analysis combined the results of two or more
exploratory analyses to calculate the third ICER, for example,
to create the ERG’s preferred base case, then this was consid-
ered to be a further separate analysis.
2. The ICER was for the technology against its principal com-
parator or in the principal scenario (its most likely use in
clinical practice).
3. When the base case or preferred ICER reported by the
company, ACD, or FAD was a range or multiple ICERs (e.g.,
for subgroups or scenarios), then the lowest ICER was used.
4. If no ICER was reported but a technology was considered in
the ACD or FAD to be “a cost-effective use of NHS [National
Health Service] resources,” then it was deemed to be so at a
threshold of £20,000 per quality-adjusted life-year (QALY)
gained, on the basis of the perceived importance of the
£20,000 per QALY threshold for NICE decision making [7].
5. If the ACD or FAD simply stated that the technology was
“dominated,” then it was assumed that it was not cost-
effective.
6. The data on whether the analyses are mentioned by the ACD
or FAD, or inﬂuenced their recommendation, relate to the
exploratory analyses described in the ERG report or a speciﬁc
addendum document (rather than any analyses conducted
between the ACD and FAD).
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Table 1 – Summary of categories of exploratory
analysis present in ERG reports produced for the
NICE STA process.
Category Deﬁnition
Fixing errors The ERG considered that something was
unequivocally wrong in the company’s
submitted model.
Addressing
violations
The ERG considered that the NICE reference
case, scope, or best practice had not been
adhered to for one or more parameters or
values, including missing out relevant key
comparators, and hence the model was not
ﬁt for purpose.
Matters of
judgment
The ERG did not consider that the submitted
model was wrong as such, but amended
the model by conducting an analysis (often
a sensitivity or threshold analysis) to test
uncertainties within the evidence or
model, or because reasonable alternative
assumptions could be applied. These could
be hypothetical or based on alternative
data in the published literature or provided
by a company.
ERG-preferred
base case
The ERG conducted its own speciﬁc preferred
base-case analysis. This might be the
result of a series of exploratory analyses.
This base case might still not be ideal from
the ERG’s perspective.
ERG, evidence review group; NICE, National Institute for Health
and Care Excellence; STA, single technology appraisal.
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7. If any work was conducted by a company between an ACD
and an FAD, it was assumed that it was critiqued by the ERG
as a standard procedure (explicit requests by an AC for an ERG
to conduct such work were rarely recorded in the ACD).
8. Evidence of inﬂuence on a recommendation required an
explicit reference to an ERG’s exploratory analysis or its ICER.
Results
Between September 2009 and September 2014, 100 STAs were
undertaken by NICE that resulted in the production of guidance.
In these 100 STAs, 40 different companies submitted documents
as part of the NICE STA process. Full details of the disease areas
covered, companies, and speciﬁc ERGs are reported in the article
by Kaltenthaler et al. [2].
The Critique of the Submission
The ERG reports and their exploratory analyses
Most of the ERG reports (93%) for the STA process conducted and
reported one ormore exploratory analyses: seven ERG reports did not
contain any exploratory analysis that generated a new ICER [8–14]. In
the 93 reports that did include an exploratory analysis, the number
of analyses ranged from 1 to 29, with an approximate mean of 8.5
analyses per report (798 analyses in 93 reports) and a median of 7 [2].
For the purposes of this research, the synthesis reduced these key
data to whether an STA conducted more or less than the overall
mean number of exploratory analyses. This approach permitted an
analysis that made the most of the data without “stretching” it too
far. For the 93 ERG reports that generated at least one exploratory
analysis, the type of analysis that appeared in the largest proportion
of reports was the category “Matters of judgment,” that is, the ERG
considered there to be uncertainty or possible variation regarding the
evidence used to populate the model. At least one such exploratory
analysis was conducted in 89% of the ERG reports. Some examples of
text from ERG reports that are illustrative of “Matters of judgment”
analyses are provided in T3Table 3 [15,16].
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Table 2 – Summary of data extraction tool.
Section Details of ﬁelds
Basic characteristics  STA title
 ERG
 Company
 Disease area
 Prespeciﬁed subgroups or end-
of-life criteria applied?
Extractors selected from a
prespeciﬁed list of variables
for most ﬁelds.
Company’s base-case ICER(s)  What is the ICER for the single
technology against the
principal comparator(s)?
 What are the ICERs for the
technology against the next
best nondominated or baseline
comparators?
 What type of model was
submitted?
Number and type of
exploratory analyses
conducted by ERG
 See Table 1. Extractors selected
from a prespeciﬁed list of
categories.
 Data extracted included the
source(s) of alternative data,
when reported.
ACD  What was the preferred ICER
and its source?
 What was the recommendation
(prespeciﬁed list of variables)?
 Did the ACD mention one or
more of the exploratory
analyses and was an ICER
mentioned?
 Did one or more exploratory
analyses inﬂuence the AC’s
recommendation (i.e., is the
analysis or its ICER cited
speciﬁcally in relation to the
recommendation)?
Additional work  Was additional work
undertaken by the company
and/or ERG between the ACD
and the FAD?
FAD  What was the preferred ICER
and its source?
 What was the recommendation
(prespeciﬁed list of variables)?
 Did the ACD mention one or
more of the exploratory
analyses and was an ICER
mentioned?
 Did one or more exploratory
analyses inﬂuence the
AC’s recommendation
(i.e., is the analysis or its
ICER cited speciﬁcally in
relation to the
recommendation)?
AC, Appraisal Committee; ACD, appraisal consultation document;
ERG, evidence review group; FAD, ﬁnal appraisal determination;
ICER, incremental cost-effectiveness ratio; STA, single technology
appraisal.
Table 3 – Illustrative examples of the “Matters of
judgment” category.
Quotation/extract
“In the MS the manufacturer uses the following utility values from
the Oxford Outcomes study for PFS: PFS1 ¼ 0.88 (disease free);
PFS2 ¼ 0.79 (remission/full response to therapy). The ERG
considers that there should be no difference in the utility values
used in the model to describe PFS1 and PFS2 as both groups of
patients are in “remission/full response.” When corrected by the
ERG, this revision has the effect of reducing the QALY gain in
PRIMA PFS by more than 10% and will therefore increase the
ICER by approximately 11%.” [15]
“In the manufacturer’s base case it is assumed that the frequency
of cardiac monitoring is greater when the patient is receiving
epirubicin than when receiving trastuzumab. However, the ERG
clinical advisors suggested that cardiac monitoring may not
routinely be undertaken when treating patients with epirubicin.
Consequently, the ERG undertook an additional sensitivity
analysis which assumed that the monitoring frequency for
epirubicin is equal to that for trastuzumab. This increased the
ICER to È50,816 per QALY.” [16]
ERG, evidence review group; ICER, incremental cost-effectiveness
ratio; MS; PFS; QALY, quality-adjusted life-year; PRIMA Q6.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ] 3
As a category of exploratory analysis, the calculation of a new
base case by an ERG appeared in 48% of reports. For some text
examples of this type of analysis, including the impact of these
analyses on the base-case ICER [16,17], seeT4 Table 4.
Much less frequent were analyses that were concerned with
either ﬁxing unequivocal errors in the submitted models (35%) or
addressing violations (18%). The total numbers for all types of
analysis add up to more than 100% because an ERG report could
include more than one type of analysis. Some illustrative
examples of noted errors and violations in ERG reports are
provided in T5Table 5 [15,17].
The ACs
The ACs’ recommendations
Following the discussion of the ERG report and other factors, ACs
produce their ACDs. In 19 STAs an FAD was issued without the
previous publication of an ACD because the submission and
appraisal dictated that further major work was not required. An
interim ACD was, however, produced for most of the STAs (81 of
100) because a positive recommendation without restrictions was
not forthcoming. In the 81 STAs with an ACD, the ACDs reported
few initial positive recommendations (18%), but most of the FADs
certainly did so (72%) (see T6Table 6). Over the 100 STAs as a whole,
it is easy to see the dramatic change in recommendations
between the decisions recorded in the ACD and the ﬁnal recom-
mendation reported in the FAD, suggesting that a process of
scrutiny, consultation, negotiation, and speciﬁcation is at work
(see Table 6).
The ACs’ preferred ICERs
A summary of the ICERs submitted by companies, and the
relationship with the preferred ICERs of ACs, as outlined in the
ACDs and FADs, is presented in T7Table 7.
It is apparent how many technologies appear to be
cost-effective at a threshold of £20,000 per QALY gained in the
original company submissions, and how few maintain that level
of cost-effectiveness after appraisal and the production of the
ACD. Most of the ACDs (72 of 81; 89%) recorded preferred or most
plausible ICERs that were greater than £20,000 per QALY gained,
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Table 4 – Illustrative examples of the “ERG base-
case” category.
Quotation/extract
“To explore the potential impact of altering a range of separate
assumptions simultaneously the ERG undertook two
‘alternative base case’ analyses which altered key assumptions
of the manufacturer’s model for which alternative estimates or
assumptions were considered equally plausible to those
employed by the manufacturer … The combined impact of
making these three changes to the model changed the
comparator to EOX and increased the ICER of HCX vs EOX to
£66,982 per QALY.”[16]
“New model results were generated by the ERG to take account of
each of the issues previously identiﬁed … the separate effect of
each change is shown in the upper section of Table 6-1
compared to the manufacturer’s submitted base-case analysis.
…The combined effect of these changes is to increase the
incremental cost attributable to use of pemetrexed by 35% as
well as reducing the incremental QALYs gained by 2%, so that
the ICER increases from £33,732 to £47,239 per QALY gained.”
[17]
EOX; ERG, evidence review group; HCXQ7 ; ICER, incremental cost-
effectiveness ratio; QALY, quality-adjusted life-year.
Table 5 – Illustrative examples of the “Fixing errors”
and “Addressing violations” categories.
Quotation/extract
Fixing errors
“The submitted model uses data from the … trial to estimate the
proportion of patients failing from the ﬁrst PFS period … but
who did not progress to second-line induction therapy. These
proportions were calculated relative to the whole randomised
population, but are applied in the model only to those patients
still alive at the end of PFS. The ERG’s correction of this anomaly
has only a minor effect on the base-case estimates, increasing
both incremental costs and outcomes, and raising the ICER by
£19 per QALY gained.” [15]
“A minor [arithmetic] error has been detected in calculating the
proportion of patients assumed to receive docetaxel and
erlotinib in second-line therapy. When this is corrected the ICER
for the manufacturer’s base case rises slightly to £33,817 per
QALY gained.” [17]
Addressing violations
“The manufacturer has failed to implement discounting correctly
according to UK practice (i.e. applied annually). … This change
increased the incremental overall discounted cost per patient by
£736 (þ3.9%) and incremental discounted QALYs per patient by
0.019 (þ1.6%), resulting in the ICER increasing by £370 per QALY
gained.” [15]
ERG, evidence review group; ICER, incremental cost-effectiveness
ratio; PFSQ8 ; QALY, quality-adjusted life-year.
Table 6 – Proportions of types of decisions in ACDs
and FADs.
Decision type Number of reports
ACD (n ¼ 81)
Recommended 10 (13%)
Optimized 4 (5%)
Minded No 19 (23%)
No 48 (59%)
FAD (n ¼ 100)
Recommended 51 (51%)
Optimized 21 (21%)
No 28 (28%)
ACD, appraisal consultation document; FAD, ﬁnal appraisal
determination.
Table 7 – Differences between the base-case ICERs
submitted by companies and the ICERs preferred by
the ACDs.
Company base-case ICER to ACD-
preferred ICER
Number of reports
(n ¼ 81)
No change (o£20,000) 9 (11%)
From o£20,000 to 4£20,000 4 (5%)
From o£20,000 to “no preferred” or “no
plausible ICER”
20 (25%)
From 4£20,000 to “no preferred” or “no
plausible ICER”
13 (16%)
No change (4£20,000) 35 (43%)
ACD, appraisal consultation document; ICER, incremental cost-
effectiveness ratio.
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or stated that there was no plausible ICER because of uncertain-
ties within the evidence and model. By the production of the FAD,
almost half of the STAs (43%) had achieved a preferred ICER of
£20,000 or £30,000 per QALY gained, or less, and all 43 technol-
ogies received a positive recommendation (seeT8 Table 8). These
included the19 STAs without an ACD, 15 (i.e., 79%) of which had a
company’s ICER less than £20,000 per QALY gained.
Nevertheless, we know that, by the production of the FAD, 72
STAs had received a positive recommendation, out of which 29
STAsQ5 received a positive recommendation with a preferred ICER
in excess of £30,000 per QALY gained, underlining that this
“threshold” is only a guide. In only 9 of the 72 STAs did the ACs
conclude that the technology satisﬁed NICE’s end-of-life criteria,
which permit higher ICERs [2]. Nevertheless, another 12 STAs
with high ICERs, and which took account of end-of-life criteria,
failed to gain a positive recommendation.
The Inﬂuence of the ERGs’ Exploratory Analyses
The ICERs preferred by ACs were often higher than the base-case
ICER submitted by a company. This is principally a consequence
of the exploratory analyses conducted by the ERG. It is not the
case that these ERG analyses simply always generated a single,
higher base-case ICER than that submitted by the company. In
fact, the ERG analyses would most often generate a number of
different ICERs, with the aim of testing the ﬁndings of the
submission and providing useful information for the committees
on the basis of different scenarios. A typical example can be
found in the STA on rivaroxaban for the prevention of stroke and
systemic embolism in atrial ﬁbrillation [18]. The company sub-
mission reported a base-case ICER of £18,883 per QALY for
rivaroxaban versus its principal comparator, warfarin. The ERG
conducted 21exploratory analyses concerning the warfarin com-
parison, generating a range of new ERG-preferred base-case ICERs
up to £62,568 per QALY gained. The conclusion of the ﬁrst AC was
that it did not consider the estimates of cost-effectiveness of
rivaroxaban compared with warfarin from the present model to
be appropriate, but accepted the ERG base case that the ICER was
likely to be up to £62,568 per QALY. The ﬁnal decision, after
further analyses, was that the most plausible ICER was between
£2,870 (the company’s post-ACD analyses) and £29,500 per QALY
gained, and so the ICER was within the range that could be
considered a cost-effective use of NHS resources. The company’s
ICER was therefore relevant, and exploratory analyses generated
the highest ICER, but the ﬁnal decision was made on the basis of
consideration of a range of ICERs.
T9Table 9 presents the source of the ICERs preferred by the ACs,
as stated in the ACDs and FADs from the STAs included in this
analysis. Often, more than one preferred ICER was presented in
the documents and the source of the preferred ICER was not
always clear in the ACD and FAD. Of the 81 STAs with ACDs, in
most cases there was either no preferred ICER (38%) or the ICERs
presented by the ERG were preferred by the AC (36%). More often
than not, however, the most preferred ICERs included estimates
from both the company and the ERG.
The ACs’ recommendations
On the basis of the explicit referencing of exploratory analyses or
their ICERs in the text of the ACDs and FADs that outlined the
committees’ decisions, the work of the ERG had a clear inﬂuence
on recommendations (see T10Table 10).
The original ERG exploratory analyses, presented in the ERG
reports, appear to have inﬂuenced recommendations in a smaller
proportion of FADs (47%) than ACDs (72%). This can be explained
by the work conducted between the ACD and the FAD: the ERG
exploratory analyses inﬂuence the ACD, which impels the com-
pany to conduct more work, including rerunning analyses and
generating new ICERs. It was rare for the ACD to mention a
speciﬁc request for an ERG to conduct further analyses or critical
appraisal, and when this did occur, it usually took place before
the ACD. For example, it was stated in an addendum to one
report that the ERG had been “requested to provide additional
analyses for the STA of aripiprazole for the treatment of schiz-
ophrenia in adolescents (aged 15–17 years) … Can an indication
of the cost-effectiveness of the ﬁrst-line aripiprazole strategy
compared with a ﬁrst-line risperidone strategy be provided using
the estimated costs for risperidone (for adolescent schizophrenia)
and the manufacturer’s economic model?” [19]. Nevertheless, it
was most often the case for there to be no speciﬁc request made
to the ERG at all, but rather a company would be required to
conduct additional work in response to a negative recommenda-
tion in the ACD, and this work would then be critiqued further by
the ERG. Sixty of the 81 STAs with an ACD (71%) involved
additional work being performed by the ERG between the pro-
duction of the ACD and the FAD. Of these, 97% (58 of 60) had
received a “No” or “Minded No” recommendation in the ACD,
with the ACD-preferred ICER being classiﬁed as either “unspeci-
ﬁed” (20 of 60; 33%) or £20,000 or more per QALY gained (38 of 60;
63%). Finally, inevitably, another factor that inﬂuenced ﬁnal
recommendations was the submission by a company of a patient
access scheme (PAS). A PAS was submitted after the production
of the ACD in 23 of these STAs and led to a positive change in
recommendation in 65% (15 of 23) of cases.
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Table 8 – FAD ICERs.
FAD ﬁnding Number of reports
(n ¼ 100)
With preferred ICER o£20,000* 37
With preferred ICER £20,000–
£30,000
6
With preferred ICER 4£30,000 36
AC did not specify a preferred ICER† 21
AC, Appraisal Committee; FAD, ﬁnal appraisal determination;
ICER, incremental cost-effectiveness ratio.
* Including ranges with at least one ICER less than £20,000 or an
acknowledgment that the technology is cost-effective at the
£20,000 threshold.
† Includes FADs without an ICER in which the analysis was based
on “costs” alone.
Table 9 – Sour
Q9
ce of preferred ICERs for ACDs and FADs.
ERG Company Both ERG and company No preferred ICER Unclear
ACD (n ¼ 81) 29 (36%) 9 (11%) 7 (9%) 31 (38%) 5 (6%)
FAD (n ¼ 100) 27 (27%) 23 (23%) 17 (17%) 24 (24%) 9 (9%)
ACD, appraisal consultation document; ERG, evidence review group; FAD, ﬁnal appraisal determination; ICER, incremental cost-
effectiveness ratio.
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Discussion
As demonstrated by the frequency, number, and type of analyses
performed, ERG exploratory analyses were not conducted simply
to generate a single, alternative ICER, but rather to present a
number of corrections and scenario analyses, presumably with
the intention of allowing an AC to decide which ICER it preferred
as being the most appropriate or relevant. The aim was to ensure
that the AC had sufﬁcient robust information to reach a decision.
When it was deemed that this had not been provided by the
company, the ERG was responsible for undertaking what they
determined to be the most appropriate exploratory analyses.
ERGs not only test the company model but also aim to anticipate
what information the AC will need to make its decisions. At least
one of the exploratory analyses conducted and reported by an
ERG is mentioned in 97% of the ACDs and had a clear inﬂuence on
more than two-third of ACD recommendations. The inﬂuence of
these original exploratory analyses appears reduced in the FAD,
although they still had some direct inﬂuence on the ﬁnal
recommendations in almost half of the STAs. On the whole, the
inﬂuence of the original exploratory analyses becomes more
indirect: they inform the AC’s preferred assumptions, which
often form the starting point for further company analyses
undertaken after the ACD is published. Consequently, it is
apparent that the ERG exploratory analyses are highly inﬂuential
in the ACD but are necessarily superseded by the later, related,
additional work of companies and ERGs, after the ACD, including
when a PAS has been submitted, which effectively lowers the
price of the technology [2].
It cannot be assumed that the number of exploratory analyses
is an indicator of the quality of a company submission. As stated
elsewhere with reference to STAs with no such analyses [2], this
absence might be due to an ERG concluding that a model is either
of very good quality or of very poor quality. If a model is
considered to be of very poor quality, the ERG might decide that
undertaking additional exploratory analyses would add no value
to the decision-making process. Nevertheless, the type of explor-
atory analysis undertaken certainly might function as a guide to
the quality of the economic model in a company submission. If
the ERG is performing analyses to ﬁx errors or address violations,
then this suggests that there were unequivocal issues with the
perceived quality of the submitted model. In this sample, ERGs
conducted at least one such analysis, respectively, in 35% and
18% of STAs. “Matters of judgment,” however, was the principal
type of analysis found in this sample of STAs: 89% of ERG reports
with analyses contained at least one such analysis. ERGs there-
fore frequently saw value in exploring multiple alternative
scenarios.
Research has found that there are similarities in the economic
evaluation processes conducted for health technology assess-
ment (HTA) in different countries, especially in Europe [20], but
only one other recent study has conducted a critique of cost-
effectiveness analyses submitted by companies to an HTA proc-
ess. The study by Ghabri et al. [3,21] has explored the critical
opinions of the Economic and Public Health Evaluation Commit-
tee regarding uncertainties in the submitted cost-effectiveness
analyses of the ﬁrst 28 submissions to the French National
Authority for Health. This study classiﬁed cost-effectiveness
uncertainty using standard international (International Society
for Pharmacoeconomics and Outcomes Research) and HTA
frameworks and identiﬁed issues similar to the present study.
Ghabri et al. identiﬁed methodological, parameter, and structural
uncertainties, which map in a general way to many of the issues
being addressed by this article’s exploratory analysis categories
(e.g., the methodological uncertainties in the study by Ghabri
et al. included adherence to the reference case and required
guidelines, similar to the present study’s “Addressing violations”
category). Previously, Hill et al. [22] had also identiﬁed similar
problems with the models considered by the Australian Pharma-
ceutical Beneﬁts Advisory Committee (e.g., questions over tech-
nical aspects of the model, unsubstantiated assumptions, and
calculation errors). These studies have therefore also considered
the limitations of submitted economic models, but the present
study goes further, detailing explicitly how such limitations are
addressed within the NICE process and how far these actions
inﬂuence decision making. The ﬁndings of this study therefore
have relevance to the conduct and critique of cost-effectiveness
analyses internationally.
The strengths of this research are that this was an analysis of
the most recent 100 STAs, which offers a good summary of
present and recent practice. The development of a simple coding
scheme, the extensive piloting of the data extraction tool, and the
double-checking of all key data across the 100 STAs by at least
two experienced health economic modelers reduced the like-
lihood of inconsistency and inaccuracy in the data. In addition,
the method of synthesis was principally descriptive, which
reduced the likelihood of overstating relationships in the data,
and a reductive approach was taken to managing data that might
be affected by interpretation or by poor reporting in the original
documents.
There are, however, some limitations in this study. There are
inherent weaknesses in using documentary analysis in that the
researcher is able to analyze only what has been reported. The
level and type of detail provided in and across the ERG reports
and other documents could be very different, which made data
extraction time-consuming, difﬁcult, and at times a matter of
interpretation. The description of the analyses undertaken was
often highly speciﬁc to a particular STA and could be inconsistent
across ERG reports. This could make coding difﬁcult. The source
of ICERs cited in ACDs and FADs could also be unclear or open to
interpretation. Despite efforts to simplify the data extraction and
coding process, it was not possible to report reliably or precisely,
for example, what exact proportion of the 100s of exploratory
analyses was actually mentioned in ACDs or FADs, or inﬂuenced
their recommendations, and so this has been reduced simply to
whether “one or more” exploratory analyses were mentioned or
had an inﬂuence in any particular STA. In addition, the data did
not permit a deeper exploration of the nuances and complexities
within the analyses, for example, the types of models being used
or the implementation of the exploratory analyses, including the
sources of data [2].
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Table 10 – InfQ10 luence of exploratory analyses on NICE
recommendations.
Number of
reports
ACD
ACD mentions one or more exploratory
analyses
74 of 76 (97%)
ACD recommendation is clearly inﬂuenced
by one or more of the exploratory analyses
mentioned
55 of 76 (72%)
FAD
FAD mentions one or more exploratory
analyses
87 of 93 (94%)
FAD recommendation is clearly inﬂuenced
by one or more of the exploratory analyses
mentioned
44 of 93 (47%)
ACD, appraisal consultation document; FAD, ﬁnal appraisal deter-
mination; NICE, National Institute for Health and Care Excellence.
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Data extraction was undertaken by two research teams (Shef-
ﬁeld and York) that between them had undertaken nearly a third
of the STAs. Although this introduced a potential source of bias,
this was minimized to some extent by having neither team
extracting data from its own reports. In addition, the inside
knowledge obtained from working on so many STAs was crucially
important in interpreting the data. These limitations suggest that
caution should be exercised regarding some conclusions drawn
from the evidence, especially concerning the generalizability of
any ﬁndings.
Additional future research priorities include a prospective
qualitative study of a limited number of STAs to assess how
ERGs make decisions regarding which exploratory analyses
should be undertaken, and to determine which type of explor-
atory analyses AC members ﬁnd most useful when making
recommendations. A study to explore how the presence and
extent of the exploratory analyses might vary according to the
skills, experience, and judgments of the ERGs would also be
useful, as would an in-depth analysis of the category of “Matters
of judgment.” This could be done by prospectively categorizing
the nature of the implementation of any exploratory analysis and
the data sources used, for example, whether an analysis was
based on different but equally valid assumptions or different but
equally valid sources of data. An assessment of the impact of
unequivocal errors on company ICERs would also be worthwhile.
Conclusions
Exploratory analyses are undertaken by the ERGs as part of the
NICE STA process to help inform decision making. They are
intended to provide support to ACs by addressing errors in
company submissions and conducting scenario analyses to
reduce the uncertainties surrounding a technology within a
particular health service context. The results of this study
suggest that the additional analyses undertaken by ERGs in the
appraisal of company submissions are highly inﬂuential in the
policymaking and decision-making process.
Source of ﬁnancial support: This project was funded by the
National Institute for Health Research HTA Programme. For more
details, visit http://www.nets.nihr.ac.uk/projects/hta/1415104.
The views and opinions expressed therein are those of the
authors and do not necessarily reﬂect those of the HTA Pro-
gramme, NICE, the National Institute for Health Research, the
NHS, or the Department of Health.
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